CStone Pharmaceuticals Full Year 2024 Earnings: Misses Expectations

CStone Pharmaceuticals (HKG:2616) Full Year 2024 Results

Key Financial Results

• Revenue: CN¥407.2m (down 12% from FY 2023).
• Net loss: CN¥91.2m (loss narrowed by 75% from FY 2023).
• CN¥0.071 loss per share (improved from CN¥0.29 loss in FY 2023).

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

2616 Post-Clinical Trial Products

• Pre-registration: 4.
• Approved (during full year): 4.

All figures shown in the chart above are for the trailing 12 month (TTM) period

CStone Pharmaceuticals Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 15%. Earnings per share (EPS) also missed analyst estimates.

The primary driver behind last 12 months revenue was the Mainland China segment contributing a total revenue of CN¥293.4m (72% of total revenue). The largest operating expense was Sales & Marketing costs, amounting to CN¥133.8m (40% of total expenses). Over the last 12 months, the company's earnings were enhanced by non-operating gains of CN¥4.15m. Explore how 2616's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 25% growth forecast for the Biotechs industry in Hong Kong.

Performance of the Hong Kong Biotechs industry.

The company's shares are down 4.7% from a week ago.

Balance Sheet Analysis

While earnings are important, another area to consider is the balance sheet. We've done some analysis and you can see our take on CStone Pharmaceuticals' balance sheet.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.